Kirkland Represents Cinven on Investment in BioAgilytix
Kirkland & Ellis advised Cinven, a leading international private equity firm, on its investment in BioAgilytix, a leading global contract research organization (‘CRO’) providing bioanalytical services to pharmaceutical and biotech companies. Cobepa, the current majority investor, will re-invest a significant minority stake alongside Cinven. Founded in 2008, BioAgilytix focuses on complex large molecule bioanalytical services, particularly for fast growing and innovative treatments, including cell and gene therapies. The transaction is subject to customary approvals. Financial details of the transaction are not disclosed.
The Kirkland team was led by corporate partners Sean Rodgers and Kate Willson and associates Mikhaila Martin and Dylan Drex Treadwell, and debt finance partners Omar Raddawi and Judson Oswald and associate Brittany Taylor.
